Evidence map›Paper›PMID 41373706›Full record

ArticleInternational journal of molecular sciences2025

Creatine Kinase Blockade Disrupts Energy Metabolism and Redox Homeostasis to Suppress Osteosarcoma Progression.

Shingo Kishi, Rika Sasaki, Rina Fujiwara-Tani, Hitoshi Ohmori, Yi Luo, Kiyomu Fujii, Takamitsu Sasaki, Kei Goto, Yoshihiro Miyagawa, Isao Kawahara and 6 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Creatine kinase regulates energy metabolism and growth of trophoblasts.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shingo KishiDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Rika SasakiDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Rina Fujiwara-TaniDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Hitoshi OhmoriDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Yi LuoDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Kiyomu FujiiDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Takamitsu SasakiDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Kei GotoDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Yoshihiro MiyagawaDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Isao KawaharaDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Ryoichi NishidaDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.ORCID 0009-0008-6517-8420
Shota NukagaDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Yukiko NishiguchiDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Ruiko OgataDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.
Kanya HonokiDepartment of Soft Tissue Sarcomas, School of Medicine, Nara Medical University, Kashihara 634-8522, Japan.ORCID 0000-0001-6763-0478
Hiroki KuniyasuDepartment of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan.ORCID 0000-0003-2298-8825

Funding

Ministry of Education, Culture, Sports, Science and Technology 23K10481Ministry of Education, Culture, Sports, Science and Technology 24K14281Ministry of Education, Culture, Sports, Science and Technology 25K14462Ministry of Education, Culture, Sports, Science and Technology 25K22766
6 · The paper itself

Abstract

Osteosarcoma is the most common primary malignant bone tumor in adolescents and young adults; yet survival outcomes have remained stagnated for decades, underscoring the urgent need for new therapeutic strategies. Creatine kinase (CK)-comprising cytosolic CKB and mitochondrial CK-maintains malignant behaviors by supporting high-energy phosphate transfer through the phosphocreatine (pCr) shuttle. Here, we pharmacologically inhibited CK activity in osteosarcoma models and evaluated proliferation, cell death modalities, mitochondrial function, stemness, motility, and tumor behavior. CK blockade consistently suppressed growth and clonogenicity and induced apoptosis as the predominant mode of death. It impaired ATP buffering capacity and disturbed mitochondrial homeostasis, accompanied by reduced expression of stemness-associated markers and diminished migration and invasion. In mouse models, CK inhibition significantly restrained tumor progression and dissemination. These results indicate that disabling the CK-pCr energy-buffering system reprograms cellular energetics toward apoptosis and less aggressive phenotypes. Our findings support targeting the CK pathway as a tractable metabolic vulnerability and a rational partner for cytotoxic regimens, with pathway-specific signaling alterations representing downstream consequences of central energetic collapse.

Indexed as

Bone NeoplasmsCreatine KinaseEnergy MetabolismHomeostasisOsteosarcomaAnimalsApoptosisCell Line, TumorCell ProliferationDisease ProgressionHumansMiceMitochondriaOxidation-ReductionCreatine Kinasecreatine kinase Bdinitrofluorobenzenmitochondrial creatine kinaseosteosarcomaphosphorylation signal pathway

Identifiers

PMID41373706
PMCPMC12692347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.